Psychiatric Drug Development: Diagnosing a Crisis
When it comes to funding drug research to treat depression, schizophrenia, anxiety, and other psychiatric disorders, the global pharmaceutical industry prefers to invest its research dollars in cancer, metabolism, autoimmunity, and other disease areas. This comes despite the fact that one in five Americans currently take at least one psychiatric drug and that mental disorders are recognized worldwide. The author traces the evolution of psychiatric drug development, the reasons for its retreat, and what needs to change to meet the growing demand.
Updating the Diagnostic and Statistical Manual of Mental Disorders
How the foremost clinical manual for psychiatric disorders guides doctors to diagnoses has long been controversial. Now, during the early stages of the manual’s revision, complementary articles—one by four scientists involved in the process, the other by a psychiatrist looking in from the outside—address how to make psychiatric diagnosis both more certain and more flexible.
Are We “Blaming” Brain Chemistry for Mental Illness?
A decade ago, if you told your doctor you were depressed, drinking too much, or having obsessive thoughts, you would have been referred to a psychotherapist to probe your early childhood experiences. Today, your doctor might give you a prescription and one follow up visit. Psychiatrist Dennis Charney and psychologist Elliot Valenstein exchange views on the scientific foundations of biological psychiatry—the understanding of mental illness in terms of the biochemistry of the brain.